PMID- 25678954
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150214
LR  - 20200930
IS  - 2042-0188 (Print)
IS  - 2042-0196 (Electronic)
IS  - 2042-0188 (Linking)
VI  - 6
IP  - 1
DP  - 2015 Feb
TI  - Dapagliflozin in patients with type 2 diabetes mellitus.
PG  - 29-41
LID - 10.1177/2042018814558243 [doi]
AB  - Dapagliflozin is a selective and reversible inhibitor of sodium-glucose linked 
      transporter type 2 (SGLT2), which mediates approximately 90% of active renal 
      glucose reabsorption in the early proximal tubule of the kidney. Dapagliflozin 
      significantly reduces glucose reabsorption and decreases serum glucose 
      concentration in an insulin-independent manner. The decrease of glucose 
      reabsorption by dapagliflozin has also been associated with a reduction in body 
      weight. Furthermore, the drug modestly reduces blood pressure levels through 
      weight loss and its action as osmotic diuretic. Dapagliflozin has been approved 
      as monotherapy in patients with type 2 diabetes mellitus (T2DM) who cannot 
      tolerate metformin or in combination with other antidiabetic drugs, with the 
      exception of pioglitazone due to the theoretical increased risk of bladder 
      cancer. The drug should not be prescribed in patients with moderate or severe 
      renal impairment or in patients at risk for developing volume depletion. 
      Dapagliflozin is associated with increased incidence of genital and lower urinary 
      tract infections, but these infections are usually mild to moderate and respond 
      to standard antimicrobial treatment. Based on current evidence, dapagliflozin is 
      a useful drug for patients with T2DM with a favorable safety profile. However, 
      further research regarding the effects of dapagliflozin on cardiovascular 
      outcomes is needed.
FAU - Filippatos, Theodosios D
AU  - Filippatos TD
AD  - Assistant Professor of Internal Medicine Department of Internal Medicine, School 
      of Medicine, University of Ioannina, Ioannina, Greece.
FAU - Liberopoulos, Evangelos N
AU  - Liberopoulos EN
AD  - Assistant Professor of Internal Medicine Department of Internal Medicine, School 
      of Medicine, University of Ioannina, Ioannina, Greece.
FAU - Elisaf, Moses S
AU  - Elisaf MS
AD  - Department of Internal Medicine, School of Medicine, University of Ioannina, 45 
      110 Ioannina, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ther Adv Endocrinol Metab
JT  - Therapeutic advances in endocrinology and metabolism
JID - 101532143
PMC - PMC4321869
OTO - NOTNLM
OT  - adverse effects
OT  - blood pressure
OT  - body weight
OT  - dapagliflozin
OT  - diabetes mellitus
OT  - drug interactions
OT  - metabolic effects
OT  - sodium-glucose linked transporter type 2 inhibitors
COIS- Conflict of interest statement: This review was conducted independently; no 
      company or institution supported it financially. The authors have given talks, 
      attended conferences and participated in trials and advisory boards sponsored by 
      various pharmaceutical companies.
EDAT- 2015/02/14 06:00
MHDA- 2015/02/14 06:01
PMCR- 2015/02/01
CRDT- 2015/02/14 06:00
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2015/02/14 06:01 [medline]
PHST- 2015/02/01 00:00 [pmc-release]
AID - 10.1177_2042018814558243 [pii]
AID - 10.1177/2042018814558243 [doi]
PST - ppublish
SO  - Ther Adv Endocrinol Metab. 2015 Feb;6(1):29-41. doi: 10.1177/2042018814558243.